ClinicalTrials.gg
CompletedNCT01620060Updated Apr 8, 2016Results posted

Lurasidone Pediatric Pharmacokinetics Study

A Phase 1 interventional study of Lurasidone in Schizophrenia and Autism, sponsored by Sumitomo Pharma America, Inc.. Completed at 10 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
21st of 39
105 · median 149
Started
2012
with 4 others
Phase 1
9 of 39
none open now
Registered
21st of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 21st largest by enrollment, is one of 5 that started in 2012, is one of 9 in phase 1, and was the 21st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric disorders.

Read the detailed description

To characterize lurasidone PK profile following single and multiple oral doses of 20, 40,80, 120 or 160 mg/day lurasidone in the targeted pediatric/adolescent population (6-17 years old)with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder or other psychiatric disorders. Data from this study will be used to recommend pediatric doses that result in comparable exposures to those observed in currently approved adult doses of Latuda® (40, 80, 120 and 160 mg/day) in subsequent efficacy and safety studies.

03

Conditions studied

  • Schizophrenia
  • Autism

Keywords

  • Schizophrenia
  • autism
  • bipolar
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must provide written , if emancipated, written assent and be willing to participate in the study. Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' adherence to the study procedures must be obtained for subjects who are not emancipated.
  • Male or female subjects 6 to 17 years of age, inclusive. Subject must be 17 years or less at the follow-up visit.
  • Subject is judged by the investigator to be clinically stable (ie, no psychiatric hospitalization within the past 12 weeks; no imminent risk of suicide or injury to self, others or property; no recent addition, or change in dosage, of psychotropic medication intended for the treatment of the primary psychiatric condition in the past 4 weeks) but symptomatic (ie, some active symptoms of the primary psychiatric condition are present for which an atypical antipsychotic agent is judged to be an acceptable treatment option).
  • Subjects with the following diagnoses will be eligible for participation: primary schizophrenia spectrum diagnosis (schizophrenia, schizoaffective, schizophreniform or psychotic disorder Not Otherwise Specified (NOS), bipolar spectrum disorder (bipolar I, II or bipolar NOS), pervasive developmental disorder (PDD) including autistic spectrum disorder (autistic disorder, Asperger's syndrome, or Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), attention-deficit hyperactivity (ADHD) with aggressive behavior [meeting co-morbid diagnostic criteria for Conduct Disorder/Disruptive Behavior Disorders Not Otherwise Specified (CD/DBD NOS), or Tourette's syndrome, via clinical interview (using MINI-Kid plus diagnostic interview and the , 4th edition Text Revision (DSM-IV-TR) as a reference). Autistic disorder should also be confirmed by the Autism Diagnostic Interview, Revised (ADI-R).
  • Within 5th to 95th percentile for gender specific weight-for-age and height-for-age Growth Charts from National Center for Health Statistics.
  • No abnormal laboratory values.
  • No clinically relevant abnormal vital sign values/findings.
  • Females who participate in this study:
  • are unable to become pregnant (eg, premenarchal, surgically sterile etc) -OR-
  • are willing to remain sexually abstinent (not engage in sexual intercourse) from Day 1 to 30 days after discharge on Day 11; -OR-
  • are sexually active and willing to use an effective method of (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from Day -1 to 30 days after discharge on Day 11.
  • Males must be willing to remain sexually abstinent or use an effective method of birth control (eg, condom) from Day -1 to 30 days after discharge on Day 11.
  • Willing and able to remain off any antipsychotic medication other than lurasidone for the duration of the study, if, in the investigator's opinion the subject is not at risk for worsening symptoms.
  • Willing and able to swallow the size and number of lurasidone tablets specified per protocol.
  • Willing and able to adhere to protocol-specified meal requirements during dosing.
  • Have a stable living arrangement for at least 3 months prior to Day -1 and agrees to return to a similar living arrangement after discharge on Day 11. Homeless subjects may not be enrolled.

Exclusion criteria

Exclusion Criteria:

  • neurological, metabolic (including type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder such as unstable angina, congestive heart failure (uncontrolled), or central nervous system (CNS) infection that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.
  • Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if under control) must be discussed with the Medical Monitor before being enrolled to the study.
  • Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, Parkinson's disease, or other forms of dementia, myasthenia gravis, or other degenerative processes. In addition, subjects must not have a history of mental retardation or persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.
  • Known presence or history of hepatic insufficiency or subject's estimated is \< 80 mL/min/1.73 m2 by the following Bedside Schwartz equation for use with creatinine methods with calibration traceable to isotope dilution mass spectrometry (IDMS): Creatinine clearance (mL/min/1.73 m2) = (0.41 height) / serum creatinine concentration, where height in cm and serum creatinine in mg/dL.
  • Clinically significant finding(s) on physical examination determined by the investigator to pose a health concern to the subject while on study.
  • A history or presence of abnormal , which in the investigator's opinion is clinically significant. Screening ECGs will be centrally over-read, and eligibility will be determined based on the over-read.
  • Known history or presence of clinically significant intolerance to any antipsychotic medications including but not limited to angioedema, serotonin or neuroleptic malignant syndromes, moderate to severe dystonia, or moderate to severe tardive dyskinesia.
  • Clinically significant alcohol abuse/dependence or drug abuse/dependence based on MINI-Kid criteria within the last 6 months prior to screening.
  • Clinically significant orthostatic hypotension (ie, a drop in systolic blood pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or more within 3 minutes of standing up).
  • Presence or history (within the last year) of a medical or surgical condition (eg, gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
  • Positive breath alcohol test at screening or on Day -1.
  • Positive test results at screening or on Day -1 for:
  • Urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, cannabinoids, and methadone). However, a positive test for amphetamines, barbiturates, opiates, benzodiazepines or methadone may not result in exclusion of subjects if the investigator determines that the positive test is as a result of prescription medicine(s).
  • Pregnancy test (only in female subjects ≥ 8 years old).
  • Lifetime history of (HIV) positive or acquired immune deficiency syndrome (AIDS), or history of or C, or a positive test for Hepatitis B or C at screening (for subjects without a history).
  • Participated in another clinical trial or receiving an product within 30 days prior to study drug administration.
  • Use of any inhibitor or inducer of taken within 28 days prior to drug administration and until discharge on Day 11. Exceptions (eg, for grapefruit juice consumption) may be discussed on a case-by-case basis with the medical monitor.
  • Use of concomitant medications that consistently prolong the /QTc interval within 28 days prior to Day -1 to follow-up.
  • Received depot neuroleptics unless the last injection was at least 1 month or 1 treatment cycle prior to Screening, whichever is longer.
  • Received treatment with antidepressants within 3 days, fluoxetine or olanzapine plus fluoxetine combination within 28 days, MAO inhibitors within 14 days prior to Day -1 to follow-up.
  • Use of any antipsychotic medication (other than study drug), carbamazepine, oxcarbazepine or fluvoxamine, within 3 days prior to Day -1 (7 days prior to Day -1 for aripiprazole) and until follow-up.
  • Does not tolerate venipuncture or has any bleeding disorder that would complicate blood drawing.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Donation or loss of whole blood within 60 days prior to drug administration.
  • Has a prolactin concentration greater than or equal to 100 ng/mL at screening.
  • Unwilling to abstain from vigorous exercise from Days -1 to 1 and from Days 9 to 10.
  • Subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the C-SSRS.
  • Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property during the study. Subject has a history of one or more serious suicide attempts (based on the investigator's judgment) in the 12 months prior to screening. Subjects determined to be at risk of suicide or injury, as assessed by the investigator at screening, will be referred for further psychiatric evaluation.
  • Clinically relevant history of drug to lurasidone or any components in the formulation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Lurasidone oral tablets

    Lurasidone 20, 40, 80, 120 or 160 mg/day

    Drug: Lurasidone

Interventions

  • Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days

06

What researchers measure

Primary outcomes

  1. Lurasidone Primary Pharmacokinetic Parameters

    Lurasidone AUClast (Day 1) and AUC0-∞ (Day 1) AUC0-24 (Day 10 or Day 12)

    Time frame: Day 1 - pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, and 48 hours. Day 10/12: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours

  2. Lurasidone Peak Serum Concentration (Cmax)

    Cmax will be listed and summarized in tabular format

    Time frame: Day 1 - pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, and 48 hours. Day 10/12: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours

Secondary outcomes

  1. Number of Participants With Serious Adverse Events and Non-serious Adverse Events

    Serious adverse event and adverse events data will be listed and summarized as per MedDRA V15.0

    Time frame: 11 Days

07

Results

Posted Jul 31, 2014

Participant flow

Total subjects randomized was 105. Total subjects with PK data was 102.

Participant flow — Overall Study
MilestoneLurasidone Oral Tablets
Started105
Completed90
Not completed15
Withdrew: Adverse event9
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1
Withdrew: Did not comply with study produre1
Withdrew: Family emergency1
Withdrew: Per sponsor decision2

Outcome measures

PrimaryLurasidone Primary Pharmacokinetic Parameters

Lurasidone AUClast (Day 1) and AUC0-∞ (Day 1) AUC0-24 (Day 10 or Day 12)

Time frame:
Day 1 - pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, and 48 hours. Day 10/12: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours
Reported as:
Mean · ng.h/mL
Lurasidone Primary Pharmacokinetic Parameters
ng.h/mLLurasidone Oral Tablets
AUC last (ng.h/mL) -Day 1 20 mg n=1678 ± 44.9
AUC last (ng.h/mL) -Day 1 40 mg n=24140 ± 65.4
AUC last (ng.h/mL) -Day 1 80 mg n=54300 ± 140
AUC0-24 (ng.h/mL) -D 10/12 20 mg n=16115 ± 72.2
AUC0-24 (ng.h/mL) -D10/12 40 mg n=21154 ± 67.4
AUC0-24 (ng.h/mL) -D10/12 80 mg n=17387 ± 194
AUC0-24 (ng.h/mL) -D10/12 120 mg n=16494 ± 271
AUC0-24 (ng.h/mL) -D 10/12 160 mg n=13590 ± 227
AUC0-∞(ng.h/mL) -D 1 20 mg n=1683.8 ± 48.3
AUC0-∞(ng.h/mL) -D 1 40 mg n=19153 ± 69.8
AUC0-∞(ng.h/mL) -D 1 80 mg n=50328 ± 163
PrimaryLurasidone Peak Serum Concentration (Cmax)

Cmax will be listed and summarized in tabular format

Time frame:
Day 1 - pre-dose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, and 48 hours. Day 10/12: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours
Reported as:
Mean · ng/mL
Lurasidone Peak Serum Concentration (Cmax)
ng/mLLurasidone Oral Tablets
Cmax (ng/mL)-Day 1 20 mg n=1624.4 ± 14.1
Cmax (ng/mL)-Day 1 40 mg n=2438.3 ± 22.4
Cmax (ng/mL)-Day 1 80 mg n=5568.2 ± 37.5
Cmax (ng/mL)-D10/12 20 mg n=1630 ± 18
Cmax (ng/mL)-D10/12 40 mg n=2136.2 ± 17.5
Cmax (ng/mL)-D10/12 80 mg n=1780 ± 59.6
Cmax (ng/mL)-D10/12 120 mg n=1694.2 ± 46.6
Cmax (ng/mL)-D10/12 160 mg n=1399.7 ± 44.3
SecondaryNumber of Participants With Serious Adverse Events and Non-serious Adverse Events

Serious adverse event and adverse events data will be listed and summarized as per MedDRA V15.0

Time frame:
11 Days
Reported as:
Number · participants
Number of Participants With Serious Adverse Events and Non-serious Adverse Events
participantsLurasidone Oral Tablets
Number of Participants With Serious Adverse Events and Non-serious Adverse Events105

Adverse events

Collected over June 19, 2012 through May 6, 2013. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone Oral Tablets—2/105 (1.9%)76/105 (72.4%)
Most frequent serious events
Most frequent serious events
EventLurasidone Oral Tablets
ParkinsonismNervous system disorders1/105
DystoniaNervous system disorders1/105
Most frequent other events
Most frequent other events
EventLurasidone Oral Tablets
SomnelenceNervous system disorders44/105
SedationNervous system disorders19/105
NauseaGastrointestinal disorders18/105
VomitingGastrointestinal disorders16/105
Upper Abdominal PainGastrointestinal disorders6/105
AnxietyPsychiatric disorders6/105
DystoniaNervous system disorders5/105
DyskinesiaNervous system disorders5/105

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lurasidone Oral Tablets
<=18 years105
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone Oral Tablets
Female37
Male68
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lurasidone Oral Tablets
Black or African American23
White82
Region of Enrollment
Region of Enrollment(participants)Lurasidone Oral Tablets
United States105
08

Study locations

10 sites
  • Woodland International Research Group, Inc.
    Little Rock, Arkansas 72223, United States
  • Woodland Northwest Research, LLC
    Springdale, Arkansas 72704, United States
  • World Wide Research Centers Inc.
    Murrietta, California 92562, United States
  • Segal Institute for Clinical Research
    Ft. Lauderdale, Florida 33301, United States
  • Miami Children's Hospital
    South Miami, Florida 33143, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • University of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • CRI Worldwide, LLC
    Philadelphia, Pennsylvania 19139, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
09

References and documents

Publications

  • Findling RL, Goldman R, Chiu YY, Silva R, Jin F, Pikalov A, Loebel A. Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. Clin Ther. 2015 Dec 1;37(12):2788-97. doi: 10.1016/j.clinthera.2015.11.001. Epub 2015 Nov 26. PubMed 26631428 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2012
First posted
Jun 15, 2012
Start
Jun 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Jul 31, 2014
Last update
Apr 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01620060
Responsible party
Sponsor
First posted
Jun 15, 2012
Start date
Jun 2012
Primary completion
May 2013
Completion
May 2013
Results posted
Jul 31, 2014
Last update
Apr 8, 2016

Study contacts

Lurasidone Medical Director
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion